Showing results (701-710 of 1,163) with videos related to
Sort By:
Pageof 117
The Lancet. Diabetes & Endocrinology|August 23, 2021
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trialsNaveed Sattar, Matthew M Y Lee, Søren L Kristensen, et al.American Heart Journal|November 13, 2022
Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathyJames L Januzzi, Javed Butler, Stefano Del Prato, et al.International Journal of Cardiology|June 15, 2018
LDL extracellular vesicle coagulation protein levels change after initiation of statin therapy. Findings from the METEOR trialLaura Verbree-Willemsen, Ya-Nan Zhang, Crystel M Gijsberts, et al.JACC. Heart Failure|December 27, 2016
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial VolumeCarolyn S P Lam, Michiel Rienstra, Wan Ting Tay, et al.Cardiovascular Research|March 5, 2019
Toll-like receptor 7 deficiency promotes survival and reduces adverse left ventricular remodelling after myocardial infarctionDominique P V de Kleijn, Suet Yen Chong, Xiaoyuan Wang, et al.ESC Heart Failure|March 29, 2024
Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: a meta-analysisDomenico D'Amario, Renzo Laborante, Emiliano Bianchini, et al.Circulation. Heart Failure|March 3, 2025
Impact of Multimorbidity on Mortality in Heart Failure With Mildly Reduced and Preserved Ejection FractionMingming Yang, Toru Kondo, Pooja Dewan, et al.Journal of the American College of Cardiology|December 3, 2014
Noncardiac comorbidities in heart failure with reduced versus preserved ejection fractionRobert J Mentz, Jacob P Kelly, Thomas G von Lueder, et al.The New England Journal of Medicine|August 28, 2018
Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary DiseaseFaiez Zannad, Stefan D Anker, William M Byra, et al.JACC. Heart Failure|May 25, 2023
Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure RiskMuhammad Shahzeb Khan, Matthew W Segar, Muhammad Shariq Usman, et al.Pageof 117